First patient treated in trial turning back cellular age to tackle glaucoma

The first participant has been treated in a landmark trial testing partial cellular reprogramming—activating three genes to make aged cells behave younger—in hopes of regenerating optic nerve neurons and treating glaucoma; safety is the primary focus, with low—but not zero—risk of cancer, and results will determine viability for broader use.